Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for Aromatase inhibitors as adjuvant endocrine therapy

for post-menopausal women with hormone receptor-positive early breast cancer

JULY 2006 |Incorporates published evidence to May 2005

A CLINICAL PRACTICE GUIDELINE DEVELOPED BY THE NATIONAL BREAST CANCER CENTRE* (NBCC*)

This document supplements guideline recommendation 19 about the use of tamoxifen for the management of post-menopausal women with hormone receptor-positive early breast cancer contained in the NBCC* Clinical Practice Guidelines for the Management of Early Breast Cancer,2nd edition, 2001 (page 9).1

ISBN Print: 1741270103 Online: 1741270111 CIP: 616.99449061
Cancer Australia 2011

* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Purpose

To provide statements and recommendations, based on the best available evidence, about the use of aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early invasive breast cancer.

Endorsed by:

Published using CeCC Docbook Manager